ATG/GCSF therapy for new-onset T1D: mechanistic insights and longer term outcomes / Designer combination therapy: the rationale for B cell depletion and co-stimulation blockade

This abstract has open access
Abstract Summary
Submission ID :
IDS84277
Submission Type
Abstract Topics
Benaroya Research Institute at Virginia Mason
University of Florida

Abstracts With Same Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
IDS82290
Invited
Invited
Professor Jay Skyler
IDS71294
Invited
Invited
Dr Sarah Richardson
IDS71310
Invited
Invited
Dr Richard Oram
IDS20295
Invited
Invited
Dr Helena Elding Larsson
12 visits

KEY DATES

Event dates:
Thursday 25 October - Monday 29 October 2018

Abstract submission deadline:
Monday 14 May 2018

Abstract notification:
July 2018

Early registration deadline:
Monday 3 September 2018

Registration deadline:
Monday 15 October 2018

Contact
British Society for Immunology
+44 (0)20 3019 5901
congress@immunology.org